Previous 10 | Next 10 |
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, tod...
2024-05-22 10:00:31 ET More on etc. Replimune: Continuing To Justify The Bear Thesis (For Now) Gold At $3,000 Is The Wrong Way To Think About The Precious Metal Best Buy: Poised For Growth Amid E-Commerce Threat Nvidia’s upcoming earnings has investors...
2024-05-21 17:07:24 ET More on Rezolute Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute Read the full article on Seeking Alpha For further details see: Rezolute stock rockets...
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at 5:30pm ET REDWOOD C...
2024-05-16 10:59:17 ET More on Rezolute Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute Read the full article on Seeking Alpha For further details see: Rezolute reports Q3 re...
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ...
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...
Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company,...
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FD...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that the underwr...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of i...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...